Version history

{
  "session_id": "sess_SDA-2026-04-04-gap-20260404-microglial-priming-early-ad_20260412-073015",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n{\"ranked_hypotheses\":[{\"rank\":1,\"title\":\"TREM2-ICD Nuclear Translocation as Self-Sustaining Priming Signal\",\"mechanism\":\"Proteolytic cleavage of TREM2 by ADAM10/γ-secretase releases the intracellular domain, which translocates to the nucleus and cooperates with SPI1/PU.1 at TYROBP promoter regions to establish a feedforward transcriptional circuit that locks microglia in a primed, inflammation-resolving-resistant state independent of membrane SYK/PI3K signaling.\",\"target_gene\":\"TREM2\",\"confidence_score\":0.52,\"novelty_score\":0.68,\"feasibility_score\":0.40,\"impact_score\":0.78,\"composite_score\":0.598,\"key_evidence\":\"PMID 30206223 (TREM2-ICD nuclear localization in HEK293T/RAW264.7); PMID 30550849 (SPI1-TYROBP cooperation in sorted microglial RNA-seq)\",\"testable_prediction\":\"CRISPRi-mediated blockade of TREM2 nuclear localization sequence prevents SPI1-driven TYROBP upregulation and reduces cytokine hypersecretion upon secondary challenge in human iPSC-derived microglia\",\"skeptic_concern\":\"Low-abundance, unstable ICD fragment demonstrated only in overexpression systems; endogenous nuclear accumulation in primary brain microglia under physiological conditions remains undemonstrated; cellular localization may be cell-line artifact\",\"expert_verdict\":\"Mechanistically compelling but requires primary microglial validation before translational investment; nuclear translocation inhibitors present challenging drug discovery but would be disease-modifying if confirmed\"}, {\"rank\":2,\"title\":\"NLRP3 Inflammasome Hyper-Responsiveness in Primed Microglia\",\"mechanism\":\"Prior exposure to DAMP signals (e.g., ATP, aggregated Aβ) primes microglial NLRP3 to mount exaggerated IL-1β responses upon secondary exposure, creating a self-reinforcing neuroinflammatory loop that drives tau pathology spread and accelerates neurodegeneration.\",\"target_gene\":\"NLRP3\",\"confidence_score\":0.68,\"novelty_score\":0.52,\"feasibility_score\":0.72,\"impact_score\":0.68,\"composite_score\":0.645,\"key_evidence\":\"NLRP3 KO mice show reduced Aβ pathology and improved cognition; IL-1β elevation documented in AD brains and prodromal CSF; in vitro priming protocols well-established\",\"testable_prediction\":\"Microglia-specific NLRP3 conditional knockout crossed to 5xFAD mice will show attenuation of tau hyperphosphorylation and synapse loss independent of amyloid burden\",\"skeptic_concern\":\"NLRP3 is upstream of broad inflammatory pathways; specificity to microglial priming versus general inflammatory enhancement remains unresolved; compensatory mechanisms may limit therapeutic efficacy\",\"expert_verdict\":\"Highest translational feasibility among inflammasome targets; MCC950 inhibitor already in preclinical development with favorable safety profile; pipeline-ready within 5-7 years if animal efficacy confirms\"}, {\"rank\":3,\"title\":\"sTREM2 as State-Dependent Biomarker of Microglial Priming\",\"mechanism\":\"Soluble TREM2 shed by ADAM10/ADAM17 cleavage reflects microglial activation state, with elevated CSF sTREM2 correlating with early tau pathology and representing a potential readout for microglial transition from homeostatic to primed/warning state.\",\"target_gene\":\"TREM2\",\"confidence_score\":0.70,\"novelty_score\":0.45,\"feasibility_score\":0.80,\"impact_score\":0.58,\"composite_score\":0.638,\"key_evidence\":\"Multiple independent cohorts (Knight Initiative,-banner) consistently show CSF sTREM2 elevation in early AD; correlates with tau PET and CSF p-tau181; sTREM2 levels modulated by TREM2 R47H variant\",\"testable_prediction\":\"Longitudinal sTREM2 measurement in preclinical carriers will predict conversion to MCI with superior accuracy compared to baseline amyloid alone, indicating priming precedes symptomatic decline\",\"skeptic_concern\":\"sTREM2 is a correlative biomarker, not mechanistic driver; cannot distinguish protective versus harmful microglial activation; does not resolve whether elevation reflects beneficial phagocytosis or maladaptive inflammation\",\"expert_verdict\":\"Near-term translational opportunity as stratification tool; validation studies should employ single-cell proteomics to resolve sTREM2 cellular origin; biomarker qualification path is 3-5 years if prospective trials confirm predictive value\"}, {\"rank\":4,\"title\":\"Disease-Associated Microglia (DAM) Signature as Composite Priming State\",\"mechanism\":\"TREM2-dependent acquisition of DAM transcriptional identity upon amyloid deposition involves coordinated downregulation of P2RY12/CX3CR1 and upregulation of CLEC7A/APOE, representing a staged microglial response that is initially protective but transitions to neurotoxicity when metabolic stress or aging compromises homeostatic resolution.\",\"target_gene\":\"TREM2\",\"confidence_score\":0.75,\"novelty_score\":0.42,\"feasibility_score\":0.68,\"impact_score\":0.72,\"composite_score\":0.663,\"key_evidence\":\"Single-cell RNA-seq consistently identifies DAM cluster in mouse AD models and human AD brain; TREM2 R47H impairs DAM formation; APOE4 allele exacerbates DAM inflammatory signature\",\"testable_prediction\":\"Single-nucleus ATAC-seq of TREM2 R47H vs. WT microglia will identify causative regulatory elements driving impaired DAM transition, enabling targeted epigenetic intervention\",\"skeptic_concern\":\"DAM may be epiphenomenon rather than driver; heterogeneity within cluster obscures functional subpopulations; human vs. mouse DAM identity shows species-specific divergence limiting cross-species translation\",\"expert_verdict\":\"Most comprehensive framework integrating multiple genetic risk factors; therapeutic targeting requires subpopulation-specific approach to avoid broad immunomodulation; staged intervention at early-stage DAM may preserve neuroprotection while blocking transition to dysregulation\"}],\"consensus_points\":[\"TREM2 is centrally positioned as a genetic risk factor",
  "tokens_used": "1447"
}